Dupilumab shortage status
No active shortage currently reported by the regulators Mederti tracks — 1 anticipated notice on file.
Last updated 2 Aug 2026 · sourced from official medicines regulators
- Generic name (INN)
- Dupilumab
- Brand names
- Dupixent
- ATC code
- D11AH05
- Class
- Auto-created by Agenzia Italiana del Farmaco — Carenze scraper
Recent shortage history
- Italy: resolved 13 Oct 2025 (began 13 Oct 2025)
- Italy: resolved 21 Feb 2025 (began 21 Feb 2025)
- Italy: resolved 9 Jan 2025 (began 9 Jan 2025)
- Italy: resolved 29 Nov 2024 (began 29 Nov 2024)
- Italy: resolved 26 Nov 2024 (began 26 Nov 2024)
- Italy: resolved 15 Nov 2024 (began 15 Nov 2024)
Frequently asked questions
Is Dupilumab currently in shortage?
No active shortage of Dupilumab is currently reported by any of the national medicines regulators Mederti tracks. Shortages can emerge quickly — this page updates daily from official sources.
Where does this Dupilumab shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Related medicines
Diclofenac-Potassium · Caffeine · Brimonidina · Finasteride · Tacrolimus-Monohydrate · Abrocitinib
Get alerted when Dupilumab status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.